Epigenetic mechanisms in leukemia

Advances in Biological Regulation

Volumn 52, Issue 3, 2012, Pages 369-376

  Zaidi, Sayyed K ^a   Trombly, Daniel J ^a   Dowdy, Christopher R ^a   Lian, Jane B ^a   Stein, Janet L ^a   van Wijnen, Andre J ^a   Stein, Gary S ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864567160     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2012.05.001     Document Type: Review

References (80)

1. Ali S.A., Zaidi S.K., Dacwag C.S., Salma N., Young D.W., Shakoori A.R., et al. Phenotypic transcription factors epigenetically mediate cell growth control. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:6632-6637.
2. Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N., et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Molecular and Cellular Biology 2001, 21:6470-6483.
3. Bakshi R., Zaidi S.K., Pande S., Hassan M.Q., Young D.W., Montecino M., et al. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes. Journal of Cell Science 2008, 121:3981-3990.
4. Barseguian K., Lutterbach B., Hiebert S.W., Nickerson J., Lian J.B., Stein J.L., et al. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:15434-15439.
5. Ben-Ami O., Pencovich N., Lotem J., Levanon D., Groner Y. A regulatory interplay between miR-27a and Runx1 during megakaryopoiesis. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:238-243.
6. Bernstein E., Allis C.D. RNA meets chromatin. Genes & Development 2005, 19:1635-1655.
7. Bestor T. The DNA methyltransferases of mammals. Human Molecular Genetics 2000.
8. Bonasio R., Tu S., Reinberg D. Molecular signals of epigenetic States. Science 2010, 330:612-616.
9. Bousquet M., Harris M.H., Zhou B., Lodish H.F. MicroRNA miR-125b causes leukemia. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:21558-21563.
10. Brown, N., Ramalho, M., and Pedersen, E. PML nuclear bodies in the pathogenesis of acute promyelocytic leukemia: active players or innocent bystanders? In Bioscience: a; 2009.
11. Chen J., Odenike O., Rowley J.D. Leukaemogenesis: more than mutant genes. Nature Reviews Cancer 2010, 10:23-36.
12. Chi P., Allis C.D., Wang G.G. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nature Reviews Cancer 2010, 10:457-469.
13. Corsello S.M., Roti G., Ross K.N., Chow K.T., Galinsky I., DeAngelo D.J., et al. Identification of AML1-ETO modulators by chemical genomics. Blood 2009, 113:6193-6205.
14. De Braekeleer E., Douet-Guilbert N., Morel F., Le Bris M.-J., Férec C., De Braekeleer M. RUNX1 translocations and fusion genes in malignant hemopathies. Future Oncology 2011, 7:77-91.
15. Dowdy C.R., Xie R., Frederick D., Hussain S., Zaidi S.K., Vradii D., et al. Definitive hematopoiesis requires Runx1 C-terminal-mediated subnuclear targeting and transactivation. Human Molecular Genetics 2010, 19:1048-1057.
16. Downing J.R., Higuchi M., Lenny N., Yeoh A. Alterations of the AML1 transcription factor in human leukemia. Seminars in Cell & Developmental Biology 2000, 11:347-360.
17. Duncan E.M., Allis C.D. Errors in erasure: links between histone lysine methylation removal and disease. Progress in Drug Research 2011, 67:69-90.
18. Dundr M., Misteli T. Biogenesis of nuclear bodies. Cold Spring Harbor Perspectives in Biology 2010, 2:a000711.
19. Erickson P., Gao J., Chang K.S., Look T., Whisenant E., Raimondi S., et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992, 80:1825-1831.
20. Esteller M. Epigenetics in cancer. New England Journal of Medicine 2008, 358:1148-1159.
21. Gardini A., Cesaroni M., Luzi L., Okumura A.J., Biggs J.R., Minardi S.P., et al. AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets. PLoS Genetics 2008, 4:e1000275.
22. Goldberg A.D., Allis C.D., Bernstein E. Epigenetics: a landscape takes shape. Cell 2007, 128:635-638.
23. Gottesfeld J.M., Forbes D.J. Mitotic repression of the transcriptional machinery. Trends in Biochemical Sciences 1997, 22:197-202.
24. Guo S., Lu J., Schlanger R., Zhang H., Wang J.Y., Fox M.C., et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:14229-14234.
25. Hart S.M., Foroni L. Core binding factor genes and human leukemia. Haematologica 2002, 87:1307-1323.
26. Hermann A., Gowher H. Biochemistry and biology of mammalian DNA methyltransferases. Cellular and Molecular Life Sciences 2004.
27. Herz H.-M., Nakanishi S., Shilatifard A. The curious case of bivalent marks. Developmental Cell 2009, 17:301-303.
28. Hug B.A., Lazar M.A. ETO interacting proteins. Oncogene 2004, 23:4270-4274.
29. Ilik I., Akhtar A. roX RNAs: non-coding regulators of the male X chromosome in flies. RNA Biology 2009, 6:113-121.
30. Insinga A., Pelicci P.G., Inucci S. Leukemia-associated fusion proteins. Multiple mechanisms of action to drive cell transformation. Cell Cycle 2005, 4:67-69.
31. John S., Workman J.L. Bookmarking genes for activation in condensed mitotic chromosomes. Bioessays 1998, 20:275-279.
32. Juven-Gershon T., Kadonaga J.T. Regulation of gene expression via the core promoter and the basal transcriptional machinery. Developmental Biology 2010, 339:225-229.
33. Kosik K.S. MicroRNAs and cellular phenotype. Cell 2010, 143:21-26.
34. Kwok C., Zeisig B.B., Qiu J., Dong S., So C.W.E. Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. Proceedings of the National Academy of Sciences 2009, 106:2853-2858.
35. Lee H.Y., Johnson K.D., Boyer M.E., Bresnick E.H. Relocalizing genetic loci into specific subnuclear Neighborhoods. Journal of Biological Chemistry 2011, 286:18834-18844.
36. Lee J.-S., Smith E., Shilatifard A. The language of histone crosstalk. Cell 2010, 142:682-685.
37. Lenny N., Meyers S., Hiebert S.W. Functional domains of the t(8;21) fusion protein, AML-1/ETO. Oncogene 1995, 11:1761-1769.
38. Li G., Reinberg D. Chromatin higher-order structures and gene regulation. Current Opinion in Genetics & Development 2011, 21:175-186.
39. Lian J.B., Javed A., Zaidi S.K., Lengner C.J., Montecino M.A., van Wijnen A.J., et al. Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Critical Reviews in Eukaryotic Gene Expression 2004, 14:1-41.
40. Ma H., Samarabandu J., Devdhar R.S., Acharya R., Cheng P.C., Meng C., et al. Spatial and temporal dynamics of DNA replication sites in mammalian cells. The Journal of Cell Biology 1998, 143:1415-1425.
41. Maiques-Diaz A., Chou F.S., Wunderlich M., Gómez-López G., Jacinto F.V., Rodriguez-Perales S., et al. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs. Leukemia 2012.
42. Martínez-Balbás M.A., Dey A., Rabindran S.K., Ozato K., Wu C. Displacement of sequence-specific transcription factors from mitotic chromatin. Cell 1995, 83:29-38.
43. Mavrakis K.J., Van Der Meulen J., Wolfe A.L., Liu X., Mets E., Taghon T., et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nature Genetics 2011, 43:673-678.
44. McNeil S., Zeng C., Harrington K.S., Hiebert S., Lian J.B., Stein J.L., et al. The t(8;21) chromosomal translocation in acute myelogenous leukemia modifies intranuclear targeting of the AML1/CBFalpha2 transcription factor. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:14882-14887.
45. Meyers S., Downing J.R., Hiebert S.W. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Molecular and Cellular Biology 1993, 13:6336-6345.
46. Minucci S., Maccarana M., Cioce M., De Luca P., Gelmetti V., Segalla S., et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Molecular Cell 2000, 5:811-820.
47. Nagaich A.K., Rayasam G.V., Martinez E.D., Becker M., Qiu Y., Johnson T.A., et al. Subnuclear trafficking and gene targeting by steroid receptors. Annals of the New York Academy of Sciences 2004, 1024:213-220.
48. Nucifora G., Birn D.J., Erickson P., Gao J., LeBeau M.M., Drabkin H.A., et al. Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA in patients with t(8;21) acute myeloid leukemia. Blood 1993, 81:883-888.
49. Ong C.-T., Corces V.G. Enhancer function: new insights into the regulation of tissue-specific gene expression. Nature Reviews Genetics 2011, 12:283-293.
50. Orom U.A., Shiekhattar R. Noncoding RNAs and enhancers: complications of a long-distance relationship. Trends in Genetics 2011, 27:433-439.
51. Otto F., Lübbert M., Stock M. Upstream and downstream targets of RUNX proteins. Journal of Cellular Biochemistry 2003, 89:9-18.
52. Pande S., Ali S.A., Dowdy C.R., Zaidi S.K., Ito K., Ito Y., et al. Subnuclear targeting of the Runx3 tumor suppressor and its epigenetic association with mitotic chromosomes. Journal of Cellular Physiology 2009, 218:473-479.
53. Peterson L.F., Zhang D.-E. The 8;21 translocation in leukemogenesis. Oncogene 2004, 23:4255-4262.
54. Pines J. Mitosis: a matter of getting rid of the right protein at the right time. Trends in Cell Biology 2006, 16:55-63.
55. Rhyasen G.W., Starczynowski D.T. Deregulation of microRNAs in myelodysplastic syndrome. Leukemia 2011, 26:13-22.
56. Sarge K.D., Park-Sarge O.-K. Gene bookmarking: keeping the pages open. Trends in Biochemical Sciences 2005, 30:605-610.
57. Schotte D., Pieters R., Boer Den M.L. MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 2011, 26:1-12.
58. Serrano E., Carnicer M.J., Lasa A., Orantes V., Pena J., Brunet S., et al. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias. Leukemia Research 2008, 32:944-953.
59. Speck N.A., Gilliland D.G. Core-binding factors in haematopoiesis and leukaemia. Nature Reviews Cancer 2002, 2:502-513.
60. Stein G.S., Zaidi S.K., Braastad C.D., Montecino M.A., van Wijnen A.J., Choi J.-Y.E., et al. Functional architecture of the nucleus: organizing the regulatory machinery for gene expression, replication and repair. Trends in Cell Biology 2003, 13:584-592.
61. Tang Q.Q., Lane M.D. Activation and centromeric localization of CCAAT/enhancer-binding proteins during the mitotic clonal expansion of adipocyte differentiation. Genes & Development 1999, 13:2231-2241.
62. Verschure P., Van Der Kraan I. Spatial relationship between transcription sites and chromosome territories. The Journal of Cell Biology 1999.
63. Vradii D., Zaidi S.K., Lian J.B., van Wijnen A.J., Stein J.L., Stein G.S. Point mutation in AML1 disrupts subnuclear targeting, prevents myeloid differentiation, and effects a transformation-like phenotype. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:7174-7179.
64. Wagner S., Chiosea S., Nickerson J.A. The spatial targeting and nuclear matrix binding domains of SRm160. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:3269-3274.
65. Wan G., Mathur R., Hu X., Zhang X., Lu X. miRNA response to DNA damage. Trends in Biochemical Sciences 2011, 36:478-484.
66. Wang Q., Huang Z., Xue H., Jin C., Ju X.L., Han J.D.J., et al. MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4. Blood 2008, 111:588-595.
67. Wutz A. Gene silencing in X-chromosome inactivation: advances in understanding facultative heterochromatin formation. Nature Reviews Genetics 2011, 12:542-553.
68. Yang X., Lay F., Han H., Jones P.A. Targeting DNA methylation for epigenetic therapy. Trends in Pharmacological Sciences 2010, 31:536-546.
69. Yoffey J. Human foetal haematopoiesis. British Journal of Haematology 1964.
70. Yoffey J.M. Transitional cells of hemopoietic tissues: origin, structure, and development potential. International Review of Cytology 1980, 62:311-359.
71. Young D.W., Hassan M.Q., Pratap J., Galindo M., Zaidi S.K., Lee S.-H., et al. Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature 2007, 445:442-446.
72. Young D.W., Hassan M.Q., Yang X., Galindo M., Javed A., Zaidi S.K., et al. Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:3189-3194.
73. Zahnow C.A., Baylin S.B. Epigenetic networks and miRNAs in stem cells and cancer. Molecular Cell 2010, 39:661-663.
74. Zaidi S.K., Dowdy C.R., van Wijnen A.J., Lian J.B., Raza A., Stein J.L., et al. Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network. Cancer Research 2009, 69:8249-8255.
75. Zaidi S.K., Young D.W., Choi J.-Y.E., Pratap J., Javed A., Montecino M.A., et al. The dynamic organization of gene-regulatory machinery in nuclear microenvironments. EMBO Reports 2005, 6:128-133.
76. Zaidi S.K., Young D.W., Javed A., Pratap J., Montecino M.A., van Wijnen A.J., et al. Nuclear microenvironments in biological control and cancer. Nature Reviews Cancer 2007, 7:454-463.
77. Zaidi S.K., Young D.W., Montecino M.A., Lian J.B., van Wijnen A.J., Stein J.L., et al. Mitotic bookmarking of genes: a novel dimension to epigenetic control. Nature Reviews Genetics 2010, 11:583-589.
78. Zaidi S.K., Young D.W., Pockwinse S.M., Javed A., Lian J.B., Stein J.L., et al. Mitotic partitioning and selective reorganization of tissue-specific transcription factors in progeny cells. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:14852-14857.
79. Zaratiegui M., Irvine D.V., Martienssen R.A. Noncoding RNAs and gene silencing. Cell 2007, 128:763-776.
80. Zeng C., van Wijnen A.J., Stein J.L., Meyers S., Sun W., Shopland L., et al. Identification of a nuclear matrix targeting signal in the leukemia and bone-related AML/CBF-alpha transcription factors. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:6746-6751.